Laboratorios Richmond SACIF
BCBA:RICH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Laboratorios Richmond SACIF
Accumulated Depreciation
Laboratorios Richmond SACIF
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Laboratorios Richmond SACIF
BCBA:RICH
|
Accumulated Depreciation
-37.1B
|
CAGR 3-Years
-124%
|
CAGR 5-Years
-93%
|
CAGR 10-Years
N/A
|
|
Laboratorios Richmond SACIF
Glance View
Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
See Also
What is Laboratorios Richmond SACIF's Accumulated Depreciation?
Accumulated Depreciation
-37.1B
ARS
Based on the financial report for Dec 31, 2025, Laboratorios Richmond SACIF's Accumulated Depreciation amounts to -37.1B ARS.
What is Laboratorios Richmond SACIF's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-93%
Over the last year, the Accumulated Depreciation growth was -45%. The average annual Accumulated Depreciation growth rates for Laboratorios Richmond SACIF have been -124% over the past three years , -93% over the past five years .
